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Transcription is a tightly regulated process ensuring the proper expression of numerous
genes regulating all aspects of cellular behavior. Transcription factors regulate multiple
genes including other transcription factors that together control a highly complex gene
network. The transcriptional machinery can be “hijacked” by oncogenic transcription
factors, thereby leading to malignant cell transformation. Oncogenic transcription factors
manipulate a variety of epigenetic control mechanisms to fulfill gene regulatory and
cell transforming functions. These factors assemble epigenetic regulators at target
gene promoter sequences, thereby disturbing physiological gene expression patterns.
Retroviral vector technology and the availability of “healthy” human hematopoietic CD34+
progenitor cells enable the generation of pre-leukemic cell models for the analysis of
aberrant human hematopoietic progenitor cell expansion mediated by leukemogenic
transcription factors. This review summarizes recent findings regarding the mechanism
by which leukemogenic gene products control human hematopoietic CD34+ progenitor
cell expansion by disrupting the normal epigenetic program.
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PURIFICATION AND GENETIC MANIPULATION OF HUMAN
HEMATOPOIETIC CD34+ PROGENITOR CELLS
Human hematopoietic progenitor and stem cells (HPSCs) are
characterized by high expression levels of the cell surface anti-
gens CD34 and CD133 and the lack of CD38 expression for
more primitive cells. CD34 is a member of the single-pass trans-
membrane sialomucin protein family and a cell-cell adhesion
factor expressed in some cell types, including hematopoietic cells,
endothelial cells, muscle satellite, hair follicle stem cells, and
fibrocytes. The CD34 antigen has been widely used as a cell sur-
face marker to identify and isolate HPSCs from bone marrow
or peripheral blood. However, the exact biological function of
CD34 remains largely unknown. Recent reports have demon-
strated that CD34 can alter the cell adhesion, migration, and
engraftment potential of hematopoietic progenitor cells in the
bone marrow niche (Fackler et al., 1995; Healy et al., 1995; Cheng
et al., 1996; Nielsen et al., 2007; Salati et al., 2008). For experi-
mental purposes, human CD34+ blood progenitor cells can be
obtained as a residual product following bone marrow aspiration
or blood cell apheresis subsequent to stimulation and mobiliza-
tion of bone marrow CD34+ cell precursors with granulocyte
colony stimulating factor (G-CSF). Moreover, several compa-
nies provide human CD34+ purified HPSCs that test negative
for infectivity complete with an ethical agreement for exper-
imental usage. Placenta-derived cord blood cells may also be
applied for long-term expansion experiments, as these cells dis-
play stemness and long-term engraftment potential superior to
that of adult CD34+ cells (Hao et al., 1995). Recently, it has been
shown that placenta-derived amniotic fluid stem cells express-
ing the c-KIT cell surface marker represent a new and attractive
source of primitive hematopoietic progenitors for experimental
purposes (Perin et al., 2008). Currently, two major techniques
used to enrich CD34+ cells are available, fluorescence-activated
cell sorting (FACS) and magnetic activated cell sorting (MACS).
Although FACS enables the purification of CD34+ cells, the
antibody labeling and sorting procedures act as significant cel-
lular stress stimuli. MACS represents another rapid and efficient
enrichment procedure, which has become the current standard
and most convenient method used to purify CD34+ cells (Clarke
and Davies, 2001). Magnetic labeled CD34 antibodies are used to
recover high-purity populations of CD34+ cells by passing cells
through magnetic columns (Figures 1A,B).
However, it is a challenge to achieve long-term expansion of
CD34+ progenitor cells while maintaining their immature state
ex vivo, even in the presence of highly concentrated cytokines
and supportive adherent cells of mesenchymal origin (Zhang
et al., 2008; Weisel et al., 2009). To establish ex vivo long-term
expansion using an alternative approach, leukemia-associated
oncogenes can be delivered and stably expressed by the retro-
viral gene transfer technology. The most commonly used deliv-
ery system is the gamma-retroviral vector system based on the
Moloney murine leukemia virus (Mo-MLV) genome (Kohn et al.,
1987). The murine stem cell virus (MSCV) expression vec-
tor is one of the most frequently employed gamma-retroviral
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FIGURE 1 | Purification and genetic manipulation of human
hematopoietic CD34+ progenitor cells. (A) Isolation of human CD34+
progenitor cells using a Ficoll gradient procedure and MACS column
purification following labeling with anti-CD34 microbeads. (B) FACS analysis
after MACS showing purified CD34+ cells. (C) Oncogene-mediated selection
of RUNX1/ETO-expressing human progenitor cells in ex vivo culture after
retroviral transduction with the indicated vectors co-expressing eGFP.
RUNX1/ETO-L148D, DNA-binding defective mutant. (D) FACS analysis of
CD34 surface marker expression of mock- and RUNX1/ETO-transduced
human progenitor cells at week 4. (E) Cytomorphological analysis of mock-
vs. RUNX1/ETO-expressing cells following the ex vivo selection process. (F)
Experimental design of CD34+ cell long-term expansion analyses. PBMC,
peripheral blood mononuclear cell; MACS, magnetic cell separation; MSCV,
murine stem cell virus; i, IRES, internal ribosome entry side element; eGFP,
enhanced green fluorescent protein; RN, retronectin; CFU, colony forming
unit; LTC-ICs, long-term culture-initiating cells; td, transduction.
vector systems, as it enables stable and high transgene expression
in virtually all cell types (Hawley et al., 1994). Lentiviral vec-
tors, which are based on the HIV genome, display an increased
capacity to incorporate large transgenes (up to 10 kilobases);
although, vector titers decrease when using larger inserts (Matrai
et al., 2010). Lentiviral transduction efficacy can be further
improved by concentrating the viral particles via ultracentrifuga-
tion (Naldini et al., 1996; Kanbe and Zhang, 2004). RetroNectin-
based gene transduction protocols dramatically enhance the
efficiency of retrovirus-mediated gene transfer in hematopoi-
etic suspension cells. With this system, retroviral particles are
preloaded onto RetroNectin-coated surfaces and co-localize viral
particles and target cells into close proximity, thereby markedly
increasing the transduction efficiency (Hanenberg et al., 1996).
Expression of a gene of interest is usually coupled to the
expression of a marker gene, e.g., enhanced green fluorescent
protein (eGFP), which allows for the immediate determination
of viral transduction efficacy and the identification of trans-
duced cells to assess proliferation, differentiation and cell death
(Figures 1C–F).
LEUKEMIC TRANSCRIPTION FACTORS EPIGENETICALLY
CONTROL PROGENITOR CELL EXPANSION
In principle, the term epigenetic regulation refers to any stable
mitotically perpetuated regulatory mechanism of a genome that
does not alter the primary nucleotide sequence (Jaenisch and
Bird, 2003; Oki and Issa, 2010). DNA methylation, histone mod-
ification, histone variant deposition in gene bodies and recruit-
ment of transcription-related enzymes to specific genetic loci are
the most commonly known molecular mechanisms that mediate
epigenetic phenomena. DNA methyltransferases (DNMTs) are
the key enzymes of genomemethylation, which play an important
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role in the epigenetic regulation of gene expression and repres-
sion (Jackson-Grusby et al., 2001; Jaenisch and Bird, 2003). In
general, DNMT1 maintains DNA methylation in mammalian
cells, while DNMT3A and DNMT3B act as de novo DNMTs by
methylating unmethylated CpG sites (Oki and Issa, 2010). Recent
studies have demonstrated that DNA methylation is critical for
the self-renewal and differentiation of normal and leukemic stem
cells (Hogart et al., 2012). Moreover, posttranslational modifica-
tion of histones regulates chromatin structure and transcription.
Histone acetylation and methylation alter gene expression pat-
terns and cellular behavior during the onset and progression of
oncogenesis (Ellis et al., 2009). Furthermore, repressive histone
modification mediated by Polycomb-group (PcG) complexes is
involved in the balance between the self-renewal and differenti-
ation of hematopoietic stem cells via regulation of the cell cycle.
PcG proteins are histone modifiers found in two protein com-
plexes, Polycomb Repressive Complex (PRC) 1 and PRC2, which
target cis-regulatory polycomb response elements (PREs) by nor-
mal and aberrant transcription factors (Cedar and Bergman,
2009). PRC2, the “initiating complex”, catalyzes the di- and tri-
methylation of histone H3 at lysine 27 (H3K27me3) accompanied
by the gene repression and maintenance of self-renewal programs
of leukemic stem cells (Sashida and Iwama, 2012). Following
PRC2-mediated histone methylation, the PRC1 complex (“main-
tenacnce complex”) is recruited to chromatin via binding to
H3K27me3. Forced expression of PcG genes, such as BMI1 or
EZH2, enhances the self-renewal capacity of HSCs and obviates
long-term repopulating exhaustion during serial transplantation
(Iwama et al., 2004). In the following paragraphs, we describe the
mechanism by which aberrant transcription factors deregulate
gene expression, thereby promoting hematopoietic CD34+ pro-
genitor cell expansion by forming aberrant epigenetic regulator
complexes that perturb gene expression.
RUNX1/ETO ASSEMBLES MULTIPLE EPIGENETIC REGULATORS
The transcription factor RUNX1 is one of the most frequent
genes involved in chromosomal translocations found in acute
myeloid leukemia (AML). RUNX1 is the sequence-specific DNA-
binding subunit of the core binding factor and a key regulator
of normal hematopoiesis (Zaiman et al., 1995). RUNX1 activity
can be altered by various genetic and epigenetic events, includ-
ing mutations, deletions, and chromosomal translocations. The
translocation t(8, 21) generates the RUNX1/ETO fusion protein,
which controls a highly complex gene network of several thou-
sands of genes via its RUNX1 DNA-binding domain (Martens
et al., 2012). The ETO portion contains four highly conserved
nervy homology region (NHR) domains, which together assem-
ble several transcriptionally active regulators. The ETO NHR2
and NHR4 domains are important for interaction with co-
repressor molecules such as mSIN3A, N-CoR and SMRT, which
recruit histone deacetylases (HDACs) 1–3, thereby contributing
to heterochromatin formation. RUNX1/ETO deletion mutants
lacking the NHR2 and NHR4 domains are completely defective
in their capacity to induce human CD34+ progenitor cell expan-
sion (own observation). RUNX1/ETO further directly interacts
with DNMT1, the major DNA methylating enzyme of a com-
plex containing N-CoR and mSIN3A. Recruitment of DNMT1 to
the interleukin-3 promoter causes gene repression, which can be
reverted via administration of demethylating agents (Liu et al.,
2005). The RUNX1/ETO high molecular weight complex also
contains the methyl-CpG-binding protein 2 (MeCP2), which
enhances the silencing of target genes that regulate the prolif-
eration and differentiation of hematopoietic cells (Fazi et al.,
2007). However, the central NHR1 domain provides a docking
site for the transcriptional activator p300, serving to activate
genes involved in self-renewal promotion such as ID1 and p21
(Wang et al., 2011). P300 mediates acetylation of RUNX1 itself
at two conserved lysine residues within the DNA-binding domain
and may acetylate histone tails to open chromatin. Hence, phar-
macological inhibition of p300 induces the cell growth arrest
of RUNX1/ETO-expanded human CD34+ cells by selectively
blocking its transcriptional activation function (Yamaguchi et al.,
2004; Wang et al., 2011). These reports suggest a model in
which RUNX1/ETO either epigenetically activates or represses
target genes, depending on the concurrent interaction with both
repressive elements and p300 (Figure 2). The exact fine-tuning
of specific cofactor binding may be dependent on the genomic
locus and the posttranslational modification of the RUNX1/ETO
cofactor recruitment domains. Importantly, the singular over-
expression of RUNX1/ETO has been shown to induce robust
ex vivo expansion of “healthy”, human hematopoietic CD34+
progenitor cells. The RUNX1/ETO-selected progenitor cells con-
tinue to express the CD34 antigen and are able to self-renew. The
cells can be cultured for more than 7 months while retaining
telomerase activity but remain cytokine dependent for survival
and proliferation. However, in contrast to primary AML patient
samples, RUNX1/ETO-selected progenitor cells fail to induce
leukemia development in immunocompromised NOD/SCID
mice, thereby suggesting that additional genetic events are nec-
essary for leukemia development (Mulloy et al., 2002, 2003). This
ex vivo cell expansion model was also applied to analyze second
hit mutations able to enhance the ex vivo expansion capacity of
the epigenetic regulator RUNX1/ETO. Retrovirally co-expressed
N-RAS(G12D), a frequent second hit mutation associated with
t(8, 21) AML, has been shown to increase CD34 expression lev-
els and colony formation numbers, enhance replating capacity,
rendered cells cytokine independent in growth and improved
cell engraftment in NOD/SCID mice, thereby suggesting that
N-RAS plays a critical role in the stepwise transformation of
t(8, 21) leukemia (Chou et al., 2011). However, the exact mecha-
nism bywhich RAS signaling complements the epigenetic changes
induced by RUNX1/ETO remains unclear.
MLL FUSIONS ARE POTENT INDUCERS OF CD34+ PROGENITOR CELL
EXPANSION
The MLL (mixed lineage leukemia) gene is a human homologue
of the Drosophila melanogaster trithorax gene and a recurrent tar-
get of chromosomal translocations found in acute leukemia. MLL
encodes a large multi-domain DNA-binding protein that con-
fers transcriptional activation and repression via histone mod-
ifying methyltransferase activity. Histone H3 lysine 4 (H3K4)
methylation of target gene promoter regions ensures proper
function of the RNA polymerase II. MLL mediated trimethy-
lation of histone H3 lysine residue 4 (H3K4me3) is a critical
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FIGURE 2 | RUNX1/ETO assembles multiple epigenetic regulators.
Open chromatin (left side) and chromatin modification following
RUNX1/ETO DNA-binding and high molecular weight complex formation.
RUNX1/ETO recruits several proteins, including N-CoR, mSIN3A, HDAC,
MeCP2 and DNMT1, into a high molecular weight complex that triggers
chromatin condensation (right side), thereby repressing gene expression.
Locus-dependent, RUNX1/ETO recruits the co-activator p300 and mediates
acetylation of RUNX1 at the two conserved lysine residues and nearby
histones, thereby promoting gene transcription. Ac, acetylation; Met,
methylation; CpG, CpG site; TF, basal transcription factor.
step involved in the epigenetic maintenance of gene transcrip-
tion in hematopoietic stem and progenitor cells (Follows et al.,
2003; Krivtsov and Armstrong, 2007). Malignancies due to MLL
translocations that give rise to chimeric proteins with more
than 70 known fusion partners confer a generally poor progno-
sis. MLL/AF9, MLL/ENL, and MLL/AF4 fusions represent the
most prevalent MLL fusion protein forms. Various studies have
suggested that MLL fusion partners are generally involved in
chromatin remodeling (Krivtsov and Armstrong, 2007). MLL
fusion proteins upregulate HOX genes, which are important
regulators of hematopoietic cell maturation. Consecutively pro-
liferative hematopoietic progenitor cells rapidly expand and dis-
play a block in cellular differentiation. Aberrant expression of
HOXA9, for example, induces a myeloid differentiation block via
co-recruitment to promoter regions bound by multiple myeloid
transcription factors including PU.1, RUNX1, and C/EBPα
(Mereau and Schwaller, 2013). All fusion proteins share the N-
terminus of the MLL histone methyltransferase protein, but lack
the C-terminal SET (Su(var)3–9, enchancer-of-zeste, trithorax)
domain with intrinsic H3K4 methyltransferase activity (Slany,
2010). Three related protein complexes directly interact with
MLL fusion proteins. The polymerase-associated factor complex
(PAFc) regulates RNA polymerase II activity. The positive tran-
scription elongation factor b (P-TEFb) and histone methyltrans-
ferase DOT1L are then recruited to MLL target gene promoter
sites. P-TEFb phosphorylates the C-terminal repeat domain of
RNA polymerase II, thereby stimulating transcriptional elonga-
tion. By methylating histone H3 at lysine 79, recruited DOT1L
also positively regulates transcriptional elongation, a critical step
for maintaining MLL fusion protein-induced leukemogenesis
(Slany, 2010; Bernt et al., 2011; Ballabio and Milne, 2012). DNA
binding is achieved via the MLL N-terminus, the MLL com-
plex partner MENIN, and LEDGF. Several studies have shown
that MLL-rearranged leukemia cells treated with hypomethylat-
ing agents regain expression of tumor suppressor genes, thereby
leading to cell growth inhibition. Histone deacetylation via
direct recruitment of HDACs to wild type MLL-bound pro-
moters may further function to promote MLL fusion protein-
triggered leukemic cell expansion and leukemogenesis (Bernt and
Armstrong, 2011). MLL translocations markedly deregulate epi-
genetic control mechanisms and may therefore require no or
only few additional mutations to cause leukemia in humans
(Armstrong et al., 2002; Neff and Armstrong, 2013). In con-
trast to AML gene rearrangements, ectopic expression of either
MLL/AF9 or MLL/ENL alone confers human CD34+ cell expan-
sion and results in myeloid or lymphoid leukemia development in
a NOD/SCID transplantation mouse model (Barabe et al., 2007;
Wei et al., 2008). Cell morphological analysis has revealed that
AML, B-ALL, and mixed lineage leukemias are associated with
both MLL rearrangements. Remarkably, even after 70 days of
ex vivo culture, the expanded progenitor cells gave rise to leukemia
development when transplanted into NOD/SCID mice. In con-
trast, MLL/AF4, which also enhances CD34+ progenitor cell
expansion, did not induce leukemia even after intra-bonemarrow
transplantation into NOD/SCID mice (Montes et al., 2011). The
underlying reason for the striking differences between individ-
ual MLL fusion genes in their ability to induce leukemia onset in
NOD/SCID mice remains almost completely unknown. A direct
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comparison of deregulated genes may reveal which additional
pathways are activated in MLL/AF9 and MLL/ENL leukemic
human CD34+ cells.
BMI1 IS ESSENTIAL FOR NORMAL AND LEUKEMIC CD34+ CELL
EXPANSION
BMI1 (B-cell specific Moloney insertion site-1) is a transcrip-
tional repressor belonging to the PcG gene family. BMI1 acts as
a chromatin regulator and is a central core component of the
PRC1 protein complex that binds at genomic loci marked by
both repressive H3K27me3 and activating H3K4me3 methylation
modifications. The PRC1 complex has no intrinsic methyltrans-
ferase activity, however, BMI1 directly interacts with the DNMT-
associated protein 1 (DMAP1) to ensure the methyltransferase
activity of DNMT1 and the proper assembly of the PRC1 com-
plex. Recognition of PRC2 methylated histone H3K27 promotes
the recruitment of the PRC1 complex. This complex subsequently
acts as a recruitment factor for E3 ligase, which is necessary
for the efficient ubiquitination of H2A-K119, thereby promot-
ing gene repression by inhibiting RNA polymerase II-dependent
transcriptional elongation and inducing chromatin condensation
(Ohtsubo et al., 2008; Schuringa and Vellenga, 2010; Nacerddine
et al., 2012). Transcriptional silencing of the INK4a locus plays a
crucial role in the maintenance of HSC self-renewal capacity reg-
ulated by BMI1, which simultaneously mediates the repression of
the p16INK4a and p19ARF genes (Sashida and Iwama, 2012). BMI1
further interferes with central tumor suppressor pathways associ-
ated with retinoblastoma protein and p53. P53 specifically binds
to the ARF locus and recruits HDACs. Deacetylation facilitates
the recruitment of PRC to the ARF locus, thereby promot-
ing H3K27 trimethylation and the silencing of ARF expression
(Zeng et al., 2011). Expression of BMI1, which is also tightly
regulated, declines once hematopoietic progenitors begin to dif-
ferentiate (Lessard et al., 1999). Forced downregulation of BMI1
in human normal CD34+ cells and acute leukemic CD34+
cells impairs their long-term expansion and self-renewal capac-
ity (Rizo et al., 2009; Harada et al., 2013). In contrast, forced
expression of BMI1 enhances the symmetrical cell division of
HSCs, their engraftment potential and the ex vivo CD34+ cell
expansion capacity (Iwama et al., 2004; Schuringa and Vellenga,
2010; Nakamura et al., 2012). It has also been suggested that
BMI1 overexpression confers protection against senescence and
apoptosis by recruiting into sites of DNA damage and histone
ubiquitination (Nakamura et al., 2012). Overexpression of BMI1
also enhances the leukemogenic activity of BCR/ABL, a fusion
protein recurrently found in chronic myeloid leukemia (CML).
Co-expression of BMI1 and BCR/ABL has been shown to trig-
ger ex vivo expansion of human CD34+ progenitor cells for
more than 20 weeks in culture and promote leukemic transfor-
mation of healthy human CD34+ cells when transplanted into
NOD/SCID mice (Rizo et al., 2010). Similarly, overexpressed
BMI1 transforms and reprograms CML B-lymphoid progeni-
tors into leukemia-initiating and self-renewing stem cells, thereby
causing B-cell acute lymphoid leukemia in vivo (Sengupta et al.,
2012). Moreover, BMI1 overexpression is frequently observed
in myelodysplastic syndrome (MDS) patients harboring RUNX1
mutations. Accordingly, a recent report has shown that BMI1
overexpression enhances the proliferation capacity of mutated
RUNX1 pre-transformed human CD34+ cells. A stepwise trans-
duction of mutated RUNX1 followed by BMI1 overexpression in
human CD34+ cells results in long-term CD34+ progenitor cell
proliferation with a retained CD34+ cell fraction similar to the
phenotype observed in patients with higher risk MDS (Harada
et al., 2013).
SYNOPSIS
The availability of “healthy” human hematopoietic CD34+ pro-
genitor cells and retroviral vector technology facilitates the estab-
lishment of models used to analyze human leukemic CD34+
progenitor cell expansion driven by leukemia-associated gene
products. Although this approach may hardly be suitable as a cell
therapeutical method for progenitor cell production due to the
danger associated with stable integrated oncogenes, the herein
described ex vivo cell expansion system allows for the precise
analysis of the molecular determinants of aberrant epigenetic
regulation that control CD34+ cell expansion. Moreover, this
cellular readout system can further be utilized to test inhibitors
targeting leukemic gene products and their epigenetic machinery
as well as to screen complex drug libraries to identify onco-
gene inhibitors. Promising candidates can be developed further
as lead compounds in preclinical cellular transformation assays
and mouse leukemia models.
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